Other studies have shown that the small molecule insulin mimetic (Compound-2) shows significant improvement in a mouse model of non-hereditary T2DM, including reducing fasting and postprandial hyperglycemia, accelerating glucose clearance, and preventing weight gain and hypertrophy of adipose tissue, as well as the development of hepatic steatosis, compared to non-thiazolidinedione (nTZD) peroxisome proliferator-activated receptor-γ agonists. This evidence concerns the gene INS and Hyperglycemia.